Document 0152
 DOCN  M95A0152
 TI    Human T cell lymphotropic virus: necessity for and feasibility of a
       vaccine.
 DT    9510
 AU    de The G; Bomford R; Kazanji M; Ibrahim F; Departement des Retrovirus,
       Institut Pasteur, Paris, France.
 SO    Ciba Found Symp. 1994;187:47-55; discussion 55-60. Unique Identifier :
       AIDSLINE MED/95317149
 AB    Human T cell lymphotropic virus types I and II (HTLV-I/II) are endemic
       in certain areas of the world. They cause two life-threatening diseases,
       adult T cell leukaemia/lymphoma and tropical spastic paraparesis. A
       vaccine is needed because in developing countries there are no other
       feasible preventive interventions against these diseases and in Western
       countries intravenous drug users at high risk for HTLV-I and HTLV-II
       infections and the health workers in contact with such populations must
       be protected. We have developed a rat model in which we observed
       variations of susceptibility to viral infection between inbred strains,
       the most susceptible being the Fischer F344, and the possibility of
       viral latency in the nervous system. We have prepared a recombinant
       adenovirus vector that expresses the HTLV-I envelope glycoprotein env in
       HeLa cells. A target human population in French Guyana, in which the
       prevalence rate reaches 5.6% in one ethnic group (Bonis), has been
       identified for possible intervention.
 DE    Disease Models, Animal  Feasibility Studies  Human  HTLV-I/*IMMUNOLOGY
       HTLV-I Infections/*PREVENTION & CONTROL  HTLV-II/*IMMUNOLOGY  HTLV-II
       Infections/*PREVENTION & CONTROL  Leukemia-Lymphoma, T-Cell, Acute,
       HTLV-I-Associated/PREVENTION &  CONTROL  Paraparesis, Tropical
       Spastic/PREVENTION & CONTROL  Support, Non-U.S. Gov't  Vaccines,
       Synthetic/*THERAPEUTIC USE  Viral Vaccines/*THERAPEUTIC USE  JOURNAL
       ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).